Abstract: The present invention relates to a method for producing an aliphatic polyester carbonate, the polyester carbonate itself, and to moulding compositions and moulded articles containing the polyester carbonate. The claimed method is characterised in particular in that the method comprises three steps and the last step is a melt transesterification method in the presence of two catalysts.

Abstract: The present invention relates to a process for preparing a polyester carbonate on the basis of aliphatic diacids and aliphatic diols and to the polyester carbonate prepared according to the process and to a moulding mass and moulding body containing the polyester carbonate. The process according to the invention is a direct synthesis in which all structural elements forming the subsequent polyester carbonate are already present as monomers in the first process step and in which two catalysts are used.

Abstract: The present invention relates to a method for preparing a polyester carbonate starting from cycloaliphatic diacids and aliphatic diols and to the polyester carbonate prepared by the method. The method according to the invention is a direct synthesis in which all the structural elements that form the subsequent polyester carbonate are already present as monomers in the first step of the method.

Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m-X1p1X2p2X3p3X4p4]z?zB+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.

Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m—X1p1X2p2X3p3X4p4]z? z B+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.